Author:
Taniguchi Yohei,Ishida Mitsuaki,Saito Tomohito,Ryota Hironori,Utsumi Takahiro,Maru Natsumi,Matsui Hiroshi,Hino Haruaki,Tsuta Koji,Murakawa Tomohiro
Abstract
AbstractThymic squamous cell carcinoma (TSQCC), accounting for 70–80% of thymic carcinoma cases, is distinct from thymoma. However, differential diagnosis for type B3 thymoma is sometimes challenging, even with established markers for TSQCC, including KIT and CD5, which are expressed in ~ 80% of TSQCCs and ~ 3% of thymomas. Novel TSQCC-specific markers would facilitate precise diagnosis and optimal treatment. Herein, we found that preferentially expressed antigen in melanoma (PRAME) may be a novel TSQCC-specific diagnostic marker. We comprehensively profiled 770 immune-related mRNAs in 10 patients with TSQCC and two healthy controls, showing that PRAME and KIT were significantly upregulated in TSQCC (adjusted p values = 0.045 and 0.0011, respectively). We then examined PRAME expression in 17 TSQCCs and 116 thymomas via immunohistochemistry. All 17 (100%) TSQCCs displayed diffuse and strong PRAME expression, whereas eight of 116 (6.8%) thymomas displayed focal and weak expression (p < 0.0001). KIT and CD5 were positive in 17 (100%) and 16 (94.1%) TSQCCs, respectively, whereas one (0.9%) type B3 thymoma showed double positivity for KIT and CD5. The KIT-/CD5-positive type B3 thymoma was negative for PRAME. Thus, combinatorial evaluation of PRAME with KIT and CD5 may facilitate a more precise diagnosis of TSQCC.
Funder
Ono Pharmaceutical Co., Ltd.
Roche
MSD
AstraZeneca
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. de Jong, W. K. et al. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur. J. Cancer 44, 123–130 (2008).
2. Travis, W. D., Brambilla, E., Burke, A. P., Marx, A. & Nicholson, A. G. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart 7 4th edn. (IARC, Lyon, 2015).
3. Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan. [Cited October 15, 2019]. https://ganjoho.jp/reg_stat/statistics/brochure/monitoring.html
4. Hishida, T. et al. Japanese Association for Research on the Thymus (JART). Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study. Eur. J. Cardiothorac. Surg. 49, 835–841 (2016).
5. Hayashi, A. et al. The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma. J. Clin. Exp. Hematopathol. 53, 9–19 (2013).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献